Leptin modification in chronic myeloid leukemia patients treated with imatinib: An emerging effect of targeted therapy.

Abstract

We evaluated serum leptin levels in 9 young chronic myeloid leukemia (CML) patients under imatinib therapy during a long-term follow-up. Body mass index (BMI) and fat mass percentage (%FM) were also measured. Leptin was above the normal range in 8 out of 9 patients. In one case the hormone was below the reference value. All subjects showed a normal BMI, but 3 had a small increase of FM%. One patient recovered the leptin normal value after imatinib suspension. A tendency to leptin normalization in patients switched to an intermittent therapy was also found. This study suggests that imatinib therapy may result in leptin alteration.

Evaluation of Serum Leptin Level in Children With Acute Leukemia

“…A study by Mariani et al on patients with CML resulted that, leptin serum level is higher than the reference ranges and in comparison of our results a similarity was found when we measured the leptin serum level in patients with acute leukaemia in terms of ALL and AML [25].…”

Nutritional status and appetite-regulating hormones in early treatment of acute lymphoblastic leukemia among children and adolescents: a cohort study

“…Another possible reason why no changes to the levels of these hormones were seen in the present study may have been the absence of energy restrictions among our population over this period. 33 According to Mariani et al, 34 use of chemotherapeutic agents can also result in modified leptin secretion over the long term, thus leading to increased plasma levels. However, the behavior of leptin reported in studies available in the literature has varied considerably.…”